Answers are grounded in this paper and cite their sources.
tumor gene 1 (WT1) encodes a zinc-finger transcription factor, originally recognized as a tumor suppressor gene in a pediatric kidney cancer, Wilms' tumor.The knockdown of WT1 powerfully stimulates the apoptosis of leukemic cells and blocks malignant cell growth.WT1 has a role in immune function, angiogenesis, cell apoptosis, adhesion and differentiation.WT1 is overexpressed (5e10 times above background levels) in 86% of patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and acute lymphoblastic leukemia (ALL) and a variety of solid cancers, but not in the normal cells, WT1 is now considered as a potential oncogene and a favorable target for cancer treatment.According to the Greglist, a database listing for quadruplex forming G-rich sequences (QGRS), theoretically many oncogenes like WT1 could form G-quadruplex structures in their GC-rich regulatory regions like promoters (promoter Gquadruplex motifs) (http://tubic.tju.edu.cn/greglist/).In our study, we explored the effectiveness of TMPyP4 to stabilize G-quadruplexes in guanine-rich DNA in WT1 oncogene.Remarkably, we found that some sequences in WT1 promoter could form G4 structures since they are recognition site for transcription factors such as H4TF1 NF-IL6, TCF-1, CTCF, AP2, and GCF that can bind the promoter of human WT1.The data of our report propose that G4 structures in WT1 promoter region may impact transcription in a negative way.First, we found some sequences in the WT1 promoter were identified by several transcription factors.Based on these findings, it was anticipated that by G4 forming, the recognition sites were unnavigable and WT1 transcription level was reduced (Fig. 1).Second, G4 structures are assumed to block transcription by preventing RNA polymerase movement.Third, G4 structures are proposed to inhibit transcription via the employment of G4-binding proteins which directly or indirectly suppress the transcription.These findings lay the foundation for the rational design and improvement of G-quadruplex-stabilizing molecules as new anticancer drugs.In addition the different molecular structures of G-quadruplexes indicate they may be differentially regulated and targeted by different molecules and more selective small molecules with G-quadruplex are being developed as potential anticancer drugs.G-quadruplex targeting drugs have lower cytotoxicity in normal cells and some of them have entered Phase II clinical trials.
No takes yet. Share an insight, caveat, or question.
Yousefnia et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: